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Abstract 31 
G protein-coupled receptor 35 (GPR35) is an orphan G protein-coupled receptor (GPCR) that 32 
can be activated by kynurenic acid at high micromolar concentrations.  A previously unappreciated 33 
mechanism of action of GPR35 has emerged as a Gαi/o-coupled inhibitor of synaptic transmission, a 34 
finding that has significant implications for the accepted role of kynurenic acid as a broad-spectrum 35 
antagonist of the NMDA, AMPA/kainite and α7 nicotinic receptors.  In conjunction with previous 36 
findings that link agonism of GPR35 with significant reduction in nociceptive pain, GPR35 has 37 
emerged as a potential effector of regulation of mechanical sensitivity and analgesia of the Ret 38 
tyrosine kinase, and as a receptor involved in the transmission of anti-inflammatory effects of aspirin– 39 
potentially through affecting leukocyte rolling, adhesion and extravasation.  Single nucleotide 40 
polymorphisms of GPR35 have linked this receptor to coronary artery calcification, inflammatory 41 
bowel disease and primary sclerosing cholangitis, while chromosomal aberrations of the 2q37.3 locus 42 
and altered copy number of GPR35 have been linked with autism, Albight’s hereditary 43 
osteodystrophy-like syndrome, and congenital malformations, respectively.  Herein, we present an 44 
update on both the pharmacology and potential function of GPR35, particularly pertaining to the 45 
nervous system.  This review forms part of a special edition focussing on the role of lipid-sensing 46 
GPCRs in the nervous system.  47 
 48 
1. Introduction 49 
 GPR35 is a poorly characterised, 7-transmembrane domain, GPCR that transmits function 50 
via interaction with Gαi/o, Gα13, and ² -arrestin (Figure 1) (Milligan, 2011; Mackenzie et al., 2011; 51 
Divorty et al, 2015; Shore and Reggio, 2015).  In terms of sequence similarity, GPR35 is related to 52 
the purinergic receptor LPA4 (32 %), the hydroxycarboxylic acid binding receptors HCA2 and HCA3 53 
(30 %), and the cannabinoid and lysophosphatidylinositol-binding GPR55 receptor (30 %) (O’Dowd 54 
et al., 1998).  As a consequence of the ligand-binding properties and shared sequence identity with 55 
GPR55, various groups have focussed on GPR35 as a putative lysophosphatidic acid-sensing GPCR 56 
(Oka et al., 2010; Zhao and Abood, 2013).  This is of interest to further investigate experimentally, 57 
although at present it is difficult to draw any conclusions based on the original findings (Oka et al., 58 
2010).  Although certainly able to be activated by high concentrations of kynurenic acid, questions of 59 
which effects of this ligand, a well-studied metabolite of tryptophan, can be attributed to activation of 60 
GPR35 remain some of the major undefined issues in understanding the function of this receptor. This 61 
is vital to examine closely because kynurenic acid is clearly neuroactive and produces a broad range 62 
of effects in the central nervous system (CNS). However, many of these effects can be attributed to 63 
blockade of ionotropic receptors for the excitatory amino acid glutamate. Specific challenges in 64 
exploring the roles of GPR35 in the CNS relate to (a) the low potency of kynurenic acid at both 65 
rodent, and particularly the human, orthologues of the receptor, (b) that although many ligands with 66 
activity at GPR35 have been reported, the vast majority of these display modest potency and are 67 
known to also have a range of non-GPR35 mediated effects and, (c) although antagonists from two 68 
distinct chemical classes have been identified, at least in transfected cell systems these appear to 69 
display exquisite selectivity for human GPR35 and lack significant affinity at either mouse or rat 70 
GPR35 (Jenkins et al., 2012).  Moreover, although a line of GPR35 knock-out mice has been 71 
generated and reported on (Min et al., 2010), these have not been employed widely and, currently, no 72 
information on the elimination of expression of GPR35 on effects of kynurenic acid in cells or tissue 73 
from the CNS has been released into the public domain.  Each of these issues will be considered 74 
within the current review. 75 
 76 
Figure 1. GPR35 couples to various effectors following agonist stimulation. RhoGEF, Ras 77 
homologue guanine nucleotide exchange factor; RhoA, Ras homologue gene family member A; 78 
cAMP, 3'-5'-cyclic adenosine monophosphate; IL-4, interleukin-4; ERK1/2, extracellular-signal 79 
regulated kinase 1/2; Ca2+, calcium. 80 
 81 
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range of effects in the central nervous system (CNS). However, many of these effects can be 83 
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from the CNS has been released into the public domain.  Each of these issues will be considered 94 
within the current review. 95 
 96 
2. Pharmacology 97 
 98 
2.1. Putative endogenous agonists of GPR35 99 
 GPR35 retains “orphan” GPCR status despite being able to be stimulated by high 100 
concentrations of a number of endogenously produced small molecules, including kynurenic acid, 2-101 
oleoyl lysophosphatidic acid, DHICA (5,6-dihydroxyindole-2-carboxylic acid), reverse T3 (3,3 ,5-102 
triiodothyronine), cGMP (cyclic guanosine 3’ 5’ monophosphate), (Wang et al., 2006; Oka et al., 103 
2010; Deng et al., 2012b; Southern et al., 2013), and, most recently, more modest levels of the 104 
chemokine CXCL17 (Maravillas-Montero et al., 2014).  This reflects that reported estimates of ligand 105 
concentration in man, under normal physiological conditions at least, are less than those required to 106 
modulate the activity of the receptor substantially (e.g. kynurenic acid, DHICA, reverse T3 and cGMP 107 
(Divorty et al., 2015)), or have been described in single publications that have not yet been verified by 108 
independent sources (e.g. CXCL17 and derivatives of lysophosphatidic acid).  The linkage of 109 
endogenously produced molecules with GPR35 activation is further complicated by marked 110 
differences in concentrations required to activate species homologues of this receptor (Milligan, 111 
2011). This has led to the suggestion that kynurenic acid could feasibly be an/the endogenous ligand 112 
of rat but not human GPR35 (Mackenzie et al., 2011).  A further point to note is that additional 113 
studies are required to verify the finding that CXCL17 is an/the endogenous ligand of GPR35 before 114 
the suggested systematic nomenclature of “CXCR8” (Maravillas-Montero et al., 2014) is agreed upon. 115 
Although this terminology has already appeared in subsequent literature (Shore and Reggio, 2015), 116 
definition of receptor de-orphanisation and adoption of a new nomenclature requires acceptance by 117 
the relevant subcommittee of the International Union of Basic and Clinical Pharmacology (IUPHAR). 118 
This has not yet occurred. 119 
 120 
2.2. Synthetic agonists of GPR35 121 
 Since there is no consensus on the endogenous ligand(s) of this receptor, a large and 122 
concerted effort in both academic (Jenkins et al., 2010; Zhao et al., 2010; Funke et al., 2013; Thimm 123 
et al., 2013) and industrial (Taniguchi et al., 2006; 2008; Yang et al., 2010; 2012; Deng et al., 2011a; 124 
2011b; 2012b) sectors; in addition to working collaborations between the two (Neetoo-Isseljee et al., 125 
2013; Mackenzie et al., 2014), has resulted in reports of a wide range of novel and previously reported 126 
small molecule agonists from both distinct, and overlapping, chemical series that are able to activate 127 
GPR35.  Such ligands include zaprinast, pamoic acid, YE-120, YE-210, tyrphostin-51, compound 128 
1/TC-G 1001, PSB-13253, lodoxamide, bufrolin, amlexanox, furosemide and cromolyn (Taniguchi et 129 
al., 2006; Zhao et al., 2010; Deng et al., 2011a, 2011b, 2012c; Neetoo-Isseljee et al., 2013; Funke et 130 
al., 2013; Mackenzie et al., 2014; Jenkins et al., 2010; Yang et al., 2010, 2012).  Because screening 131 
for GPR35 active ligands has predominantly used the human orthologue, all of these compounds have 132 
some level of potency at human GPR35. However, despite a number of ligands displaying little 133 
potency at rodent orthologues of GPR35, recently a number of rodent-selective and high and species 134 
equipotent ligands, e.g. lodoxamide and bufrolin, have been reported (Mackenzie et al., 2014).  Thus, 135 
there is now a wide selection of ligands available that have agonist activity at GPR35. A challenge for 136 
those who have not followed developments in this field closely is to select ligands with the 137 
appropriate pharmacological activity for the species of cell or tissue being studied.  Furthermore, 138 
various agonist ligands display marked differences in efficacy in distinct screening assays, and the 139 
implications of this for biological activity in cells and tissues that express GPR35 endogenously 140 
remain unclear. Moreover, as the vast majority of ligands with GPR35 agonist activity have derived 141 
from screening of commercially available compound libraries, many of the ligands identified from 142 
these screens are known to have significant and prominent effects at biological targets other than 143 
GPR35.  It is vital, therefore, that potential non-GPR35-mediated effects of such ligands are 144 
considered. 145 
 146 
2.3. Synthetic antagonists of GPR35 147 
Although substantial progress has been made in identification of agonists of GPR35, the 148 
identification and/or reporting of GPR35 antagonists has lagged behind. Indeed, representatives from 149 
only two chemical series are widely available.  Key exemplars of these series are CID-2745687 (1-150 
(2,4-difluorophenyl)-5-[[2-[[(1,1-dimethylehyl)amino]thioxomethyl]hydrazinylidene]methyl]-1H-151 
pyrazole-4-carboxylic acid methyl ester) and ML-145 (2-hydroxy-4-[4-(5Z)-5-[(E)-2-methyl-3-152 
phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid) 153 
(Heynen-Genel et al., 2010; 2011; Zhao et al., 2010).  Although far from fully characterised, there are 154 
no reports of substantial off-target effects of these compounds when used at modest concentrations. 155 
Indeed, in both these examples there is marked selectivity between GPR35 and GPR55, the most 156 
closely related member of the GPCR family. These ligands should, therefore, be expected to offer an 157 
avenue to define contributions of GPR35.  However, the use of these compounds is complicated 158 
substantially by their marked species selective behaviour. Although not evident initially (Zhao et al., 159 
2010), in transfected cell expression systems both CID-2745687 and ML-145, although derived from 160 
entirely distinct chemical series, were both found to display high affinity at human GPR35 but to 161 
display  no significant affinity for either the rat or mouse orthologues. This was the case whether 162 
monitoring their capacity to block agonist function at GPR35 in transfected cell systems using either 163 
² -arrestin-2 recruitment, receptor internalisation, or G protein-mediated signalling pathways (Jenkins 164 
et al., 2012).  Thus, as all reported studies on potential CNS function of GPR35 have used cell and 165 
tissues from rodents, the use of these antagonists would appear to be inappropriate.  However, as 166 
discussed later, this has not precluded their use in certain studies.  Despite the apparent clarity of the 167 
in vitro pharmacological studies (Jenkins et al., 2012), initial experiments did report GPR35 168 
antagonism with CID-2745687 at the mouse orthologue in a transfected cell system (Zhao et al., 169 
2010) and, subsequently, a number of functional studies have employed these antagonists in rodent 170 
models to prevent apparent GPR35 agonist responses (Berlinguer-Palmini et al., 2013; Alkondon et 171 
al., 2015).  Clearly further studies, perhaps performed in knock-out animals (Min et al., 2010), are 172 
required to clarify these discrepancies.  173 
 174 
2.4. Kynurenic acid and its biological targets 175 
A substantial number of studies have assessed the role of kynurenic acid in systems 176 
endogenously expressing GPR35, with the broad assumption that effects were produced via agonism 177 
of this receptor. Kynurenic acid is a neuroprotective, endogenous tryptophan metabolite produced by 178 
astrocytes via the kynurenine pathway (Figure 2).  Kynurenic acid is appreciated to inhibit all three 179 
classes of ionotropic excitatory amino acid receptors as a broad-spectrum competitive antagonist.  It 180 
acts at the glycine co-agonist site of the N-methyl-D-aspartate (NMDA) receptor with an IC50 of 8-15 181 
µM in the absence of glycine and 239 µM in the presence of 10 µM glycine (Kessler et al., 1989; 182 
Hilmas et al., 2001). Moreover, it inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 183 
(AMPA) and kainite receptors (IC50 10-500 µM) (Patel et al., 2001; Prescott et al., 2006; Bertolino et 184 
al., 1989; Alt et al., 2004; Mok et al., 2009).  Kynurenic acid also acts as a non-competitive inhibitor 185 
of the α7-nicotinic acetylcholine receptor (IC50 ~ 7 µM) (Hilmas et al., 2001), and as an agonist of the 186 
aryl hydrocarbon receptor (EC25 104 nM) (DiNatale et al., 2010) in addition to its action as an agonist 187 
of GPR35. 188 
At GPR35 kynurenic acid displays a degree of species selectivity, producing EC50s of 189 
between 39 – 217 µM at human, 7 – 66 µM at rat, and 11 µM at mouse (Wang et al., 2006; Zhao et 190 
al., 2010; Jenkins et al., 2011; Southern et al., 2013).  Therefore, the use of kynurenic acid in CNS-191 
derived preparations, within the concentration ranges assessed in many in vivo and ex vivo studies is 192 
likely to directly block the aforementioned glutamate receptors in addition to activating GPR35. For 193 
this reason, the role of kynurenic acid at a particular receptor tends to be dissected using antagonists 194 
of each of the glutamatergic receptor types.  Since such studies have indicated that after treatment 195 
with various glutamatergic receptor antagonists there remains a response to kynurenic acid that is able 196 
to modulate glutamate release (Carpenedo et al., 2001; Alkondon et al., 2011; Banerjee et al., 2012), 197 
then GPR35 has been considered the likely target, given its expression pattern and association with 198 
Gαi/o signalling (Berlinguer-Palmini et al., 2013).  The GPR35 antagonists described earlier have, 199 
therefore, also been employed to attempt to better define a role of GPR35 in such kynurenic acid- 200 
 201 
 202 
Figure 2. Kynurenic acid is synthesised from precursor L-kynurenine in astrocytes Kynurenic 203 
acid does not cross the blood-brain barrier but is synthesised by irreversible transamination from L-204 
kynurenine, carried out by the action of kynurenine aminotransferase II in astrocytes.  L-kynurenine, 205 
the major metabolite of tryptophan, crosses the blood-brain barrier through the large neutral amino 206 
acid carrier.  Newly formed kynurenic acid is readily liberated from astrocytes and goes on to carry 207 
out its pharmacological functions in the extracellular milieu. 208 
 209 
induced effects (Berlinguer-Palmini et al., 2013).  However, as also noted earlier, careful 210 
consideration must be given to the use of either CID-2745687 or ML-145 and interpretation of the 211 
results, as there is strong evidence that these compounds block agonist-induced signalling at human 212 
GPR35 but not at the rat or mouse forms of the receptor (Jenkins et al., 2012).  This leads to 213 
uncertainty in findings that have employed these compounds to implicate responses of GPR35 in ex 214 
vivo rodent models.  Moreover, consideration must be given to the concentration of kynurenic acid 215 
employed in native expression systems to study the activation profile of GPR35 because significantly 216 
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lower concentrations of kynurenic acid have been employed in a number of functional assays than 217 
would be anticipated to be required based on studies using cloned receptors (Wang et al., 2006; Barth 218 
et al., 2009; Cosi et al., 2011; Jenkins et al., 2011; Moroni et al., 2012).  Assigning function to a 219 
particular receptor or response is further complicated given that the AMPA and kainite receptor 220 
antagonists 6,7-dinitro-2,3-quinoxalinedione (DNQX) and 2,3-dihydroxy-6-nitro-7-sulfamoyl-221 
benzo(f)quinoxaline (NBQX) were recently shown to act as moderately potent agonists of GPR35 222 
(Southern et al., 2013).  Therefore, application of these compounds in functional studies may abrogate 223 
glutamatergic release through inhibition of AMPA receptors and agonism of GPR35, confusing 224 
studies that have associated the use of these ligands only with blockade of the AMPA/kainite 225 
receptors (Carpenedo et al., 2001).  As a result of this, it may be pertinent to also assess antagonists of 226 
the NMDA and α7 nicotinic receptors as agonists of GPR35. In a pharmacological context it is 227 
prudent, therefore, to employ a selection of structurally diverse, commercially available GPR35 228 
agonists.  This approach was taken recently in native rat hippocampal slices to strengthen the 229 
argument for a role of GPR35 in modulating neuronal activity (Alkondon et al., 2015).  It is a 230 
significant disappointment that, currently, studies employing GPR35 knock out mice have been 231 
restricted to blood pressure regulation, and other cardiovascular, endpoints (Min et al., 2010) rather 232 
than in neurobiological studies. 233 
 234 
2.6. Zaprinast and its biological targets 235 
Beyond kynurenic acid, zaprinast is the most frequently employed GPR35 agonist in 236 
functional studies.  Indeed, since its original description as an agonist of GPR35 (Taniguchi et al., 237 
2006), zaprinast has, de facto, become the reference agonist for this receptor (Yang et al., 2010; 238 
Jenkins et al., 2010; Zhao et al., 2010; Deng et al., 2011a; 2012b; Berlinguer-Palmini et al., 2013; 239 
Neetoo-Isseljee et al., 2013; Divorty et al., 2015). Widespread use of zaprinast in this context reflects 240 
the routine demonstration of its capacity to activate GPR35 and that it shows reasonable potency at 241 
various species orthologues (Taniguchi et al., 2006; Jenkins et al., 2012).  However, zaprinast is better 242 
known, and was originally described, as a relatively potent inhibitor of phosphodiesterases (PDEs) 243 
(Lugnier et al., 1986), and is most commonly reported as an inhibitor  of subclasses of cGMP-specific 244 
PDEs, including PDE5 (IC50 0.4-0.8 µM) and PDE6 (IC50 0.15 µM) (Beavo, 1995; Loughney et al. 245 
1998).  Zaprinast also modulates with reasonable potency PDE1 (IC50 0.35 µM), and with moderate 246 
potency PDE9 (IC50 35 µM), PDE10 (IC50 22-33 µM), and PDE11 (IC50 5-33 µM) (Taher et al., 1994; 247 
Fisher et al., 1998; Fujishige et al., 1999; Fawcett et al., 2000; Yuasa et al., 2000; Nakamizo et al., 248 
2003), which, in addition to GPR35, are also expressed within specific regions of the brain (Fisher et 249 
al., 1998; Bischoff, 2004; Kruse et al., 2009).  A number of studies assessing the function of zaprinast 250 
at GPR35 tend use the PDE5 inhibitor sildenafil as an independent PDE inhibitor that lacks agonism 251 
at GPR35 (Berlinguer-Palmini et al., 2013; Alkondon et al., 2015). However, potential contribution of 252 
zaprinast to inhibition of other PDEs is rarely accounted for, and considering the reported EC50 of 253 
zaprinast at human (2-8 µM), mouse (1 µM), and rat (0.1 µM) orthologues of GPR35 (Taniguchi et 254 
al., 2006; Jenkins et al., 2012), this remains a relevant concern.  255 
  256 
3. Background to GPR35 function 257 
 258 
3.1. GPR35 tissue expression profile  259 
 Interest in GPR35 in the context of neuropharmacology is relatively recent. In part, this may 260 
stem from initial studies suggesting that GPR35 was not expressed to a significant level in human or 261 
rat brain (O’Dowd et al., 1998; Wang et al., 2006).  These studies employed RNA from broad brain 262 
regions and/or relatively insensitive detection methods.  Subsequently, however, GPR35 expression 263 
has been identified within discrete regions of the CNS and peripheral nervous system, including the 264 
caudate nucleus in human, the medulla oblongata, hippocampus, spinal cord and dorsal root ganglia 265 
(DRG) of mouse (Wang et al., 2006; Cosi et al., 2011), and the DRG, spinal cord, hippocampus and 266 
cerebrum of rat (Taniguchi et al., 2006; Ohshiro et al., 2008; Berlinguer-Palmini et al., 2013; 267 
Alkondon et al., 2015).  Moreover, substantial levels of GPR35 mRNA recorded in other tissues, 268 
including high levels in immune and gastrointestinal tissue (Wang et al., 2006; Yang et al., 2010), and 269 
lower levels in heart, lung and skeletal muscle (Horikawa et al., 2000; Taniguchi et al., 2006; Leonard 270 
et al., 2007; Min et al., 2010) had focussed attention on these tissues, and diseases associated with 271 
their dysregulation, as being more appropriate to explore the function and therapeutic potential of 272 
GPR35 (Milligan, 2011). Studies that detect mRNA corresponding to GPR35 are consistent with 273 
localised CNS expression, with a number of reports expanding this to immunodetection (Ohshiro et 274 
al., 2008; Cosi et al., 2011; Franck et al., 2011; Deng et al., 2011a). Although such studies are of vital 275 
importance to confirm expression, concerns about the specificity of staining with many anti-GPCR 276 
antisera remain widespread (Michel et al., 2009) and controls employing tissue from knock-out 277 
animals are currently lacking to adequately validate antibody/antisera specificity.  278 
 279 
3.2. Identification of GPR35 and chromosomal location 280 
 GPR35 was first identified in genomic DNA through homology cloning using degenerate 281 
oligonucleotide primer sequences based on the transmembrane sequence of GPR1 (O’Dowd et al., 282 
1998).  Human GPR35, situated at chromosomal locus 2q37.3, encodes two alternatively spliced 283 
protein sequences.  GPR35a, which encodes a 309 amino acid, 7-transmembrane domain polypeptide, 284 
and GPR35b, which is identical in sequence apart from containing a 31 amino acid N-terminal 285 
extension (Okumura et al., 2004).  Although the majority of literature on human GPR35 focusses on 286 
the short (GPR35a) isoform, it is important to note that there is limited information currently available 287 
on whether GPR35a and GPR35b are differentially regulated and/or provide different functionalities 288 
in vivo.  In human gastric cancer, there does appear to be some differences between the two transcripts 289 
with GPR35b being identified from tumours and non-tumorous surrounding regions whilst GPR35a 290 
was found in the tumorous regions only, at a level lower than GPR35b, but with a higher transforming 291 
capability (Okumura et al., 2004). Such differences were not observed in primary cardiomyocytes 292 
where GPR35a and GPR35b mRNA transcripts were found to be expressed to similar levels and to 293 
respond in a similar manner to stimuli (Ronkainen et al., 2014).  Moreover, in vitro pharmacological 294 
efforts using both the long and short isoforms of GPR35 indicated that they respond with similar 295 
potency to GPR35 agonists (Guo et al., 2008; Zhao et al., 2010; Mackenzie et al., 2014). As such, any 296 
distinctiveness in function between the splice variants is not likely to reflect pharmacological 297 
variation but it is possible that the extended N-terminal domain of GPR35b may provide protein-298 
protein interactions in a native setting that would not be evident in transfected cell systems. This, 299 
however, has yet to be explored directly.  Production of these two transcript variants has only been 300 
reported for human, with transcripts akin only to the short version of human GPR35 identified in 301 
mouse and rat.  Mouse GPR35, which shares 73.4 % overall protein sequence identity with human 302 
GPR35a, translates into a protein of 307 amino acids from chromosomal locus 1D (Taniguchi et al., 303 
2006), whilst rat GPR35, which shares 72 % overall homology with human and 85 % overall 304 
homology with mouse, encodes a protein of 306 amino acids from a chromosome location of 9q36 305 
(Taniguchi et al., 2006). 306 
   307 
3.3. Genetic disorders associated with chromosomal locus 2q37.3   308 
 Chromosome 2q terminal deletions are among the most frequently reported cytogenetic  309 
abnormalities in individuals with autism spectrum disorders. The occurrence of autism or autistic 310 
features in children with deletion of chromosome 2q37.3 has been reported in a number of cases 311 
(Smith et al., 2001; Ghaziuddin and Burmeister, 1999; Falk and Casas, 2007; Devillard et al., 2010; 312 
Chong et al., 2014).  The genomic region lacking GPR35, GPC1 (glypican 1), and STK25 (serine 313 
threonine protein kinase 25) has been associated with tracheomalacia, short phalanges and eczema 314 
(Cassas et al., 2004; van Karnebeek, 2002; Falk and Casas, 2007).  However, for the majority of 315 
studies focusing on 2q37.3, the role of GPR35 has not been considered due to a lack of information 316 
regarding its expression and functionality in the nervous system.  Terminal, de novo, microdeletions 317 
of the subtelomeric long arm of chromosome 2 have also been associated with Albright’s hereditary 318 
osteodystrophy (AHO)-like syndrome and brachydactyly-mental retardation.  Patients with these 319 
disorders present with developmental delay (with mild to severe mental retardation), behavioral 320 
abnormalities, autism, obesity, short stature, brachydactyly type E, craniofacial dysmorphism, along 321 
with cardiac, tracheal, gastrointestinal, genitourinary tract and CNS abnormalities (Jensen and Hoo, 322 
2004; Chassaing et al., 2004; Fernandez-Rebollo et al., 2009).   323 
 Although AHO syndrome is characterised by an inactivating mutation in the GNAS gene 324 
encoding the stimulatory Gαs subunit (Ringel et al., 1996), functionality of this G protein is normal in 325 
AHO-like syndrome, which is often associated with de novo microdeletions at chromosome 2q37.3.  326 
Terminal deletions of chromosome 2 affect the genomic DNA sequences of at least thirty genes 327 
including GPR35, GPC1, and STK25 (Shrimpton et al., 2004).  GPR35 haploinsufficiency, arising as 328 
a result of a de novo deletion of the maternal copy of GPR35, was put forward as a plausible 329 
candidate for AHO-like and brachydactyly-mental retardation syndromes (Shrimpton et al., 2004) but 330 
this has not been extended subsequently.   331 
 Additionally, increased copy number variation of GPR35 was observed in a female foetus that 332 
upon autopsy presented with cloacal malformation with anal atresia, bilateral renal dysplasia, urethral 333 
agenesis, a secondary bell shaped thorax, and Potter syndrome, as a result of a de novo 334 
microduplication at the 2q37.3 locus (Hilger et al., 2013).  This region, spanning 25 kb, contained 335 
exons 3-4 of a CAPN10 splice variant and exons 3-6 of GPR35, of which the latter was reasoned 336 
(based on disease-association and available gene expression analysis) to be wholly or at least partly 337 
responsible for the described phenotype (Hilger et al., 2013).  These birth defects qualify for the group 338 
of “VACTERL association” disorders, which are characterised by vertebral defects (including 339 
hemivertebrae and abnormal spinal curvature), anorectal malformations, cardiac defects, 340 
tracheoesophageal fistula with or without esophageal atresia, rental malformations, and limb defects 341 
(Solomon, 2011; Siebel and Solomon, 2013).  In line with GPR35’s association with Gα13 signalling 342 
(Jenkins et al., 2010), RhoA activation and the potential role of lysophosphaditic acid species as 343 
ligands of GPR35 (Oka et al., 2010), it is interesting to speculate that GPR35 could play a role in cell 344 
polarity, which is an important feature of development critical for organ function.  However, once 345 
again, further studies, perhaps based on knock out models, are required to clarify the role of this 346 
receptor and its function under normal physiological conditions in order to ascribe these disorders to 347 
GPR35. The suggestion that species of lysophosphaditic acid may activate GPR35 is intriguing given 348 
the relatively close relatedness of GPR35 to the lysophosphaditic acid receptors LPA4, LPA5 and 349 
LPA6 (Im, 2013). 350 
 351 
4. The emerging function of GPR35 in the nervous system 352 
 353 
4.1. Modulation of synaptic transmission 354 
In an early study investigating coupling of human GPR35a and GPR35b to native neuronal 355 
signalling pathways and effectors, human GPR35 isoforms were transiently transfected into cultured 356 
rat superior cervical ganglion neurones and the effect on whole cell calcium channel currents (ICa) 357 
monitored using the patch-camp technique (Guo et al., 2008).  Using a double pulse voltage protocol 358 
it was observed that the major component of current originated from É-conotoxin GVIA-sensitive N-359 
type calcium channels (Cav2.2).  The N-type calcium channel is widely expressed in the CNS and 360 
controls neurotransmitter release, alongside P/Q- and R-type channels.  These channels are localised 361 
to presynaptic terminals, where their voltage-dependent activation leads to an influx of calcium ions, 362 
which in turn initiates exocytosis of synaptic vesicles containing various neurotransmitters (Wheeler 363 
et al., 1994).  Under native conditions there was no reduction in ICa following application of kynurenic 364 
acid (300 µM) or zaprinast (10 µM) to cultured rat superior cervical ganglion neurones.  However, 365 
when human GPR35 was transiently expressed in these cells, kynurenic acid and zaprinast inhibited 366 
ICa currents by 38 % and 59 %, respectively (Guo et al., 2008).  This led the authors to suggest that 367 
endogenous expression of rat GPR35 was absent from superior cervical ganglion neurons.  However, 368 
gene expression or immunocytochemistry were lacking in this report. Despite this, an interesting 369 
finding from this paper was the observation that GPR35 appeared to modulate ICa through G² ³  subunit 370 
activity, as voltage-dependent inhibition presented with slowed prepulse activation and partially 371 
relieved the inhibition of the depolarizing conditioning pulse following application of GPR35 agonists 372 
(Guo et al., 2008).  This profile was abolished following application of Pertussis toxin, suggesting the 373 
involvement of a GPR35-Gαi/o coupled pathway.   374 
Fast synaptic transmission is mediated synergistically by multiple types of high-voltage-375 
activated Ca2+ channels, including N-type calcium channels, in the mammalian CNS.  Therefore, it is 376 
interesting that application of GPR35 agonists to rat hippocampal slices endogenously expressing 377 
GPR35 generated a concentration- and time-dependent reduction in the frequency of spontaneous 378 
action potentials in cornu Ammon (CA)1 stratum radiatum interneurons (Alkondon et al., 2015).  379 
Responses to zaprinast, dicumarol, amlexanox, and pamoic acid were monitored using a standard 380 
patch-clamping technique and acted to reduce the frequency of fast current transients (Alkondon et 381 
al., 2015).  The GPR35 antagonist/inverse agonist ML-145 (1 µM), meanwhile, displayed the reverse 382 
effect and significantly increased the mean frequency of fast current transients.  Moreover, co-383 
application of ML-145 (1 µM) with zaprinast (10 µM) significantly reduced the inhibitory effect of 384 
zaprinast (Alkondon et al., 2015). Despite the issues with the reported lack of affinity of ML-145 at 385 
rat GPR35 (Jenkins et al., 2012), in these studies the rank-order of potency of a range of agonists was 386 
similar to that observed when employing in vitro pharmacological methods using fluorescently-tagged 387 
and overexpressing cell systems to define ligand structure-activity relationships at GPR35 (Divorty et 388 
al., 2015). This is a strong example of employing the breadth of available GPR35 pharmacology to 389 
build an argument for the direct contribution of this receptor (Alkondon et al., 2015). 390 
Agonism of GPR35 has also been demonstrated to be involved in the reduction of evoked 391 
excitatory post synaptic currents at the CA1 pyramidal neurones of the rat hippocampus, through 392 
application of both zaprinast and kynurenic acid (Berlinguer-Palmini et al., 2013).  To attempt to 393 
eliminate effects independent of GPR35 (e.g. being through kynurenic acid inhibition of NMDA and 394 
α-7 nicotinic receptors, or zaprinast inhibition of PDE5 and/or PKG), specific inhibitors were 395 
employed, and these did not affect the evoked excitatory post synaptic current in the same manner as 396 
kynurenic acid and zaprinast.  Furthermore, the effect of these ligands was ablated following pre-397 
incubation with the GPR35 antagonist/inverse agonist, CID-2745687 (Berlinguer-Palmini et al., 398 
2013).  Although the same issues of reported species specificity of CID-2745687 (Jenkins et al., 2012) 399 
clouds interpretation, in conjunction with the previously described findings it seems possible that 400 
GPR35 agonists may act to reduce the frequency of action potentials through inhibition of N-type 401 
calcium channels, leading to a smaller Ca2+ influx, a reduction in neurotransmitter release and a 402 
reduction in the evoked post synaptic current at the post-synaptic cell.   403 
 404 
4.2. Nociception, neuropathic and inflammatory pain 405 
GPR35 has been shown to be highly expressed in the DRG of both rats and mice (Ohshiro et 406 
al., 2008; Cosi et al., 2011). The DRG contains neurones that convey sensory information from the 407 
periphery to the CNS, and become an important source of increased nociceptive signalling as a result 408 
of increased neuronal excitability (Sapunar et al., 2012).  After neurogenesis of the DRG, signalling 409 
via the Ret (rearranged during transfection) tyrosine kinase receptor within the innervation targets is 410 
one of the mechanisms that shape the development of sensory neurones.  In the early stages of DRG 411 
formation, two subpopulations of large-size neurones emerge, one that contains Ret (early Ret 412 
neurones) and further differentiate into low-threshold mechanoreceptors (Bourane et al., 2009; Luo et 413 
al., 2009).  Another subpopulation of Ret containing neurones diverge later in the development of the 414 
DRG from smaller unmyelinated neurones, including nociceptors (late Ret neurones) (Franck et al., 415 
2011).  Conditional (Cre) knock out C57/BL6 mice lacking expression of Ret in nociceptive neurones 416 
were associated with a 66 % reduction in GPR35 as compared with wild type mice (Franck et al., 417 
2011).  These mice also presented with decreased sensitivity to mustard oil, had an increased 418 
sensitivity to cold in the acetone test, displayed a significant increase to cold hyperalgesia in the 419 
ischaemic nerve injury model of neuropathic pain, and displayed hypersensitivity to mechanical 420 
stimuli as indicated by a lower threshold to paw withdrawal using von Frey filaments (Franck et al., 421 
2011).  Since the Ret knock out mice did not display altered expression of typical antinociceptive 422 
receptors, and based on the altered expression of GPR35 at both a protein and mRNA level as well as 423 
the literature surrounding GPR35, the authors suggested that an inhibitory function of GPR35 on 424 
synaptic transmission by nociceptive neurones may be dysfunctional in Ret conditional knock out 425 
mice, leading to the observed behaviours (Franck et al., 2011). 426 
GPR35 has also been observed in a subpopulation of small-to-medium diameter sensory 427 
neurones that contained TRPV1 (transient receptor potential cation channel subfamily V member 1) 428 
and larger sized neurones that convey non-nociceptive information (such as touch and light pressure), 429 
which contained GPR35 but not TRPV1 (Ohshiro et al., 2008). This led the authors to suggest that 430 
GPR35 could play a role in the conversion of mechanical stimuli into nerve impulses.  TRPV1 is a 431 
non-selective cation channel that mediates Ca2+ release activity to mediate hyperalgesia, neurogenic 432 
inflammation and neuropathic pain.  The function of TRPV1 can be modulated by Gαi/o-coupled 433 
GPCRs that inhibit its activity through modulation of cAMP levels.  Linked to this, application of 434 
kynurenic acid and zaprinast resulted in a reduction of cAMP in cultured DRG that was abolished by 435 
pre-treatment with the Gαi/o inhibitor Pertussis toxin. As such, GPR35 could mediate visceral pain 436 
perception through modulating the action of TRPV1.  This has not yet been demonstrated for GPR35 437 
in any follow-up studies, although, interestingly, both the α7 nicotinic and NMDA receptors have 438 
been shown to specifically modulate the activity of TRPV1 to mediate mechanical hyperalgesia (Lee 439 
et al., 2012; Shelukhina et al., 2014).   440 
 Functional studies demonstrating activation of GPR35 and a reduction in pain perception 441 
have employed the acetic acid writhing test (Cosi et al., 2010).  Mice were pre-treated by 442 
subcutaneous injection with suitable doses of either zaprinast or kynurenic acid and, subsequently 443 
acetic acid (0.6 %) was applied through intraperitoneal injection. Writhing behaviour was then 444 
monitored.  Five mg/kg zaprinast and 300 mg/kg kynurenic acid significantly reduced writhing 445 
behaviour by 54 % and 58 % relative to phosphate buffered saline-injected control mice (Cosi et al., 446 
2010).  Following confirmation of GPR35 expression in the DRG and spinal cord of mice, functional 447 
analysis using zaprinast and kynurenic acid on isolated, cultured, glial cells revealed a Gαi/o-coupled 448 
reduction of cAMP levels following pre-stimulation with forskolin (Cosi et al., 2010).   449 
In vivo studies employing the formalin test in rats to investigate the role of zaprinast in 450 
visceral pain modulation demonstrated that pre-treatment with zaprinast (10, 30 or 100 µg) by 451 
intrathecal injection, followed by subcutaneous injection of formalin (5 %) into the planar surface of 452 
the hind paw significantly reduced the sum of flinches compared with wild type mice (Yoon et al., 453 
2005).  Specifically, zaprinast reduced flinching behaviour during phase one and two of the formalin 454 
test. The acute phase of the formalin test predominately represents C-fibre activation as a result of 455 
peripheral stimulation (Martindale et al., 2001; McCall et al., 1996), whereas the tonic phase typically 456 
represents the inflammatory response emanating from the initial stimulus, suggested to be a result of 457 
NMDA receptor activation (Davidson et al., 1997; Vaccarino et al., 1993).  The PDE5 inhibitor 458 
sildenafil and nonsteroidal anti-inflammatory drugs reduce writhing behaviour only at the late phase 459 
of the formalin test (Malmberg and Yaksh, 1992; 1993; Mixcoatl-Zecuatl et al., 2000), while systemic 460 
morphine reduces both phases (Oluyomi et al., 1992; Capuano et al., 2009; Sevostianova et al., 2003).  461 
Interestingly morphine acts in a synergistic manner with zaprinast (Heo et al., 2005), indicating that 462 
zaprinast and morphine act through distinct processes to modulate nociceptive behaviour.  However, 463 
since many of these key studies are now rather dated and were performed before a broader 464 
pharmacological tool-kit of GPR35 ligands became available, it would be of considerable interest to 465 
see a number of these studies repeated with better and more selective tool compounds. 466 
The GPR35 agonist pamoic acid has also been associated with the modulation of visceral pain 467 
in mice using the acetic acid abdominal constriction test (Zhao et al., 2010).  Pre-incubation with 468 
subcutaneous injection of pamoic acid (25, 50, and 100 mg/kg) for twenty minutes dose-dependently 469 
reduced the pain associated with intraperitoneal administration of acetic acid (0.6 %), causing 50 % 470 
antinociception at 40 mg/kg.  This was indicated to be a similar effective dose to that of acetyl 471 
salicylate (aspirin). However, as aspirin did not promote ² -arrestin-2 translocation in cells expressing 472 
GPR35, the authors suggested different mechanisms of action for these two compounds (Zhao et al., 473 
2010).  Subsequent drug screening efforts have also reported aspirin to be inactive at GPR35.  474 
However, 2,3,5-trihydroxybenzoic acid, salicyluric acid and gentisuric acid, which are metabolites of 475 
aspirin, were reported to activate human GPR35 in both dynamic mass redistribution and ² -arrestin-2 476 
recruitment assays (Deng and Fang, 2012a).  Recent literature has suggested that some of the benefits 477 
exerted by aspirin could be mediated by GPR35 (Dodd et al., 2013).  This is based in part on studies 478 
designed to understand how aspirin application inhibits acute inflammation, irrespective of its effects 479 
on the inhibition of prostaglandin synthesis.  Aspirin was found to acetylate cyclooxygenase-2 480 
(COX2) within the endothelium, resulting in the synthesis of 15-(R)-hydroxyeicosatetraenoic acid. 481 
This in turn was rapidly metabolised by leukocyte 5-lipoxygenase to 15-epi-lipoxin A4; 15-epi-lipoxin 482 
A4 then elicited nitric oxide synthesis from constitutive nitric oxide (eNOS) and inducible nitric oxide 483 
(iNOS) synthase (Paul-Clark et al., 2004).  Oral administration of aspirin (200 mg/kg), one hour prior 484 
to assessment was found to reduce IL-1² -stimulated leucocyte flux, rolling velocity, adherence and 485 
extravasation through the endothelium (Paul-Clark et al., 2004).  This provided evidence 486 
demonstrating that the mechanism of aspirin’s inhibition of acute inflammation involved modulating 487 
leukocyte function via the nitric oxide pathway.  Since these studies were carried out in vivo it is 488 
interesting to speculate upon an involvement of aspirin metabolites and agonism of GPR35 in this 489 
process, as previous studies indicate that application of kynurenic acid increases the adhesion of 490 
leukocytes to vascular endothelial cells and shedding of neutrophil L-selectin from human peripheral 491 
monocytes in a manner that was significantly reduced by short hairpin mediated silencing of GPR35 492 
(Barth et al., 2009).   493 
4.3. Neuroinflammation, mast cells and inflammatory disease 494 
 Inflammatory bowel disease and primary sclerosing cholangitis are two interlinked chronic 495 
inflammatory conditions of which the etiology is incompletely understood.  Recently, single 496 
nucleotide polymorphisms of GPR35 were found to be risk factors for early-onset inflammatory 497 
bowel disease (Imielinski et al., 2009), ulcerative colitis (Yang et al., 2015) and both ulcerative colitis 498 
and primary sclerosing cholangitis (Ellinghaus et al., 2013) through genome wide association studies.  499 
Both of these conditions are associated with significant abdominal discomfort and pain, and have been 500 
linked with changes to neurally-controlled functions (Bernstein et al., 2002; Lakhan and Kirchgessner, 501 
2010; Strack et al., 2011; Vermeulen et al., 2014).   502 
Mast cell numbers are increased in both inflammatory bowel disease and primary sclerosing 503 
cholangitis (Sasaki et al., 2002; Ishii et al., 2005), and have been suggested to contribute a direct role 504 
to the pathogenesis of inflammatory bowel disease (De Winter et al., 2011).  Mast cells are located 505 
with close apposition to afferent nerve endings and enteric neurones in the gastrointestinal tract (Stead 506 
et al., 2006; Buhner and Schemann, 2011), acting to relay information to the central nervous system 507 
(Rijnierse et al., 2007; De Winter et al., 2011).  Recent GPR35 literature indicates that a substantial 508 
number of compounds with mast cell stabilising activity are also agonists of GPR35; these include 509 
luteolin, quercetin, ellagic acid, gallic acid, dicumarol, furosemide, nedrocromil, nivimedone, 510 
cromolyn, lodoxamide, bufrolin, amlexanox, pemirolast and doxantrazole (Jenkins et al., 2010; Yang 511 
et al., 2010; Deng et al., 2012b; Deng and Fang 2012b; Yang et al., 2012; Neetoo-Isseljee et al., 2013; 512 
Southern et al., 2013; Mackenzie et al., 2014).  Moreover, cromolyn was shown to be effective in the 513 
treatment of cholangiopathy associated with primary sclerosing cholangitis as a result of reducing 514 
mast cell numbers and histamine release (Kennedy et al., 2014) whilst nedrocromil reduced 515 
inflammation and fibrosis in a rat model of colitis (Xu et al., 2002).  Although a functional link 516 
between GPR35 agonism and mast cell stabilisation remains to be demonstrated, GPR35 is expressed 517 
in mast cells and is upregulated in response to IgE stimulation (Yang et al., 2010).  GPR35 is also 518 
highly expressed in basophils and eosinophils (Yang et al., 2010), natural killer cells (Fallarini et al., 519 
2010), CD14+ monocytes, dendric cells, peripheral blood lymphocytes (Wang et al., 2006), and 520 
neutrophils (Barth et al., 2009; Wang et al., 2006), suggesting an involvement for this receptor in the 521 
immune system and potentially at the neuro-inflammatory axis. 522 
 523 
5. Conclusions 524 
 The role of GPR35 in the modulation of synaptic transmission, neurogenic and inflammatory 525 
pain, and potential signalling pathways involved in these processes are beginning to emerge.  There 526 
has previously been a disconnect between gene knockout, single nucleotide polymorphisms, and 527 
pathophysiological conditions associated with GPR35 versus the basic signal transduction pathways 528 
that emanate from this receptor under normal physiological conditions (Mackenzie et al., 2011).  With 529 
the most recent findings suggesting a GPR35-Gαi/o-linked mechanism of inhibition of synaptic 530 
transmission, and possible regulation of GPR35 by Ret tyrosine kinase (Franck et al., 2011) and 531 
hypoxia (Ronkainen et al., 2014) we are beginning to discern the basic signalling pathways of GPR35 532 
and processes regulating it’s expression.  This exciting new avenue of research expands the potential 533 
therapeutic value of GPR35 beyond that as a target for the treatment of heart failure and hypertension 534 
(Min et al., 2010; Sun et al., 2008). However, close attention to the pharmacological differences 535 
between species orthologues of GPR35 is required to better validate conclusions and the use of both 536 
cells and tissues from knock out animals will be vital to overcome concerns about effects of GPR35 537 
active ligands reflecting non-GPR35 mediated mechanisms. 538 
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